Role of radical prostatectomy in the treatment of high-risk prostate cancer

Thompson I, Thrasher JB, Aus G, et al.: Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007, 177:2106–2131.

Kane CJ, Presti JC Jr, Amling CL, et al.: Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007, 177:113–117.

Meng MV, Elkin EP, Latini DM, et al.: Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005, 173:1557–1561.

Denberg TD, Glode LM, Steiner JF, et al.: Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int 2006, 98:335–340.

Cooperberg MR, Moul JW, Carroll PR: The changing face of prostate cancer. J Clin Oncol 2005, 23:8146–8151.

Gerber GS, Thisted RA, Chodak GW, et al.: Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997, 32:385–390.

Clark PE, Peereboom DM, Dreicer R, et al.: Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001, 57:281–285.

Dreicer R, Magi-Galluzzi C, Zhou M, et al.: Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004, 63:1138–1142.

Donohue JF, Bianco FJ, Jr., Kuroiwa K, et al.: Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 2006, 176:991–995.

Lau WK, Bergstralh EJ, Blute ML, et al.: Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002, 167:117–122.

Ward JF, Slezak JM, Blute ML, et al.: Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005, 95:751–756.

Grossfeld GD, Chang JJ, Broering JM, et al.: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001, 165:851–856.

Eastham JA, Riedel E, Scardino PT, et al.: Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003, 289:2695–2700.

D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969–974.

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006, 98:839–845.

Tsai HK, Chen MH, McLeod DG, et al.: Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 2006, 107:2597–2603.

Stephenson AJ, Scardino PT, Eastham JA, et al.: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006, 98:715–717.

D’Amico AV, Chen MH, Roehl KA, Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125–135.

D’Amico AV, Chen MH, Catalona WJ, et al.: Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 2007, 110:56–61.

Bianco FJ Jr, Kattan MW, Scardino PT: PSA velocity and prostate cancer. N Engl J Med 2004, 351:1800–1802; author reply 1800–1802.

Yossepowitch O, Eggener SE, Bianco FJ Jr, et al.: Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007, 178:493–499; discussion 499.

Stephenson AJ, Scardino PT, Eastham JA, et al.: Pretreatment nomogram predicting the long-term risk of metastatic progression of prostate cancer after radical prostatectomy. J Clin Oncol 2005, 23:4545.

van den Ouden D, Hop WC, Schroder FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998, 160:1392–1397.

Hsu CY, Joniau S, Oyen R, et al.: Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007, 51:121–128; discussion 128–129.

Berglund RK, Jones JS, Ulchaker JC, et al.: Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 2006, 67:1253–1256.

Loeb S, Smith ND, Roehl KA, Catalona WJ: Intermediateterm potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007, 69:1170–1175.

Yossepowitch O, Eggener SE, Serio AM, et al.: Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2007.

Van Poppel H, Vekemans K, Da Pozzo L, et al.: Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006, 42:1062–1067.

Gontero P, Marchioro G, Pisani R, et al.: Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 2007, 51:922–929; discussion 929–930.

D’Amico AV, Manola J, Loffredo M, et al.: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004, 292:821–827.

Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103–106.

Labrie F, Cusan L, Gomez JL, et al.: Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997, 49:56–64.

Schulman CC, Debruyne FM, Forster G, et al.: 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000, 38:706–713.

Klotz LH, Goldenberg SL, Jewett MA, et al.: Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003, 170:791–794.

Soloway MS, Pareek K, Sharifi R, et al.: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002, 167:112–116.

Aus G, Abrahamsson PA, Ahlgren G, et al.: Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002, 90:561–566.

Gleave ME, Goldenberg SL, Chin JL, et al.: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001, 166:500–506; discussion 506–507.

Gleave ME, Goldenberg SL, Jewett MA, et al.: Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. Proceedings of the American Urological Association Annual Meeting. Chicago, IL; April 26–May 1, 2003.

Konety BR, Eastham JA, Reuter VE, et al.: Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004, 171:709–713.

Pettaway CA, Pisters LL, Troncoso P, et al.: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000, 18:1050–1057.

Febbo PG, Richie JP, George DJ, et al.: Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005, 11:5233–5240.

Kattan MW, Eastham JA, Stapleton AM, et al.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766–771.

Thompson IM Jr, Tangen CM, Paradelo J, et al.: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296:2329–2335.

Bolla M, van Poppel H, Collette L, et al.: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572–578.

Van der Kwast TH, Bolla M, Van Poppel H, et al.: Identi-fication of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007, 25:4178–4186.

Messing EM, Manola J, Yao J, et al.: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7:472–479.

Wirth M, Tyrrell C, Delaere K, et al.: Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis 2007, 10:87–93.